Tidal Medical Technologies receives FDA Emergency Use Authorization (EUA) for the use of InSee for tracking of incentive spirometers usage in treatment of respiratory conditions in COVID-19 patients.
Retrieved on:
Wednesday, July 14, 2021
FDA Emergency Use Authorization (EUA) issued for InSee, a patented device for tracking incentive spirometers compliance
Key Points:
- FDA Emergency Use Authorization (EUA) issued for InSee, a patented device for tracking incentive spirometers compliance
In reaching their decision, FDA said there were no approved or cleared devices for quantitatively tracking patient usage of spirometers as an aid in treatment of respiratory conditions by patients with COVID-19 in hospital settings. - Incentive spirometers are used during recovery of respiratory illness to strengthen the muscles used for breathing and increase ventilation.
- Incentive Spirometry has been used widely to help prevent pneumonia in bed-bound patients and help improve lung capacity in Respiratory patients, like COVID-19.
- With the InSee, hospitals will have objective data and smart-monitoring to better help the prevention and treatment of respiratory conditions."